Predictive value of a clinical score for overall survival following curative radiotherapy for lung cancer
Open Access
- 19 June 2026
- journal article
- research article
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (25) , e49314
Abstract
This study retrospectively calculated the LabPS score (laboratory parameters + performance status) in patients with small-cell lung cancer (SCLC) and non-SCLC who were treated with curative radiotherapy. The score was derived from pretreatment laboratory parameters – including hemoglobin level, platelet count, serum lactate dehydrogenase, serum albumin, and serum C-reactive protein – and Eastern Cooperative Oncology Group (ECOG) performance status (PS). The primary aim was to investigate the association between the LabPS score and overall survival (OS). The LabPS score was calculated retrospectively by reviewing pretreatment routine complete blood counts, biochemistry results, and ECOG PS of patients diagnosed with lung cancer and treated with radiotherapy. Patients who underwent radiotherapy with curative intent were selected. Patients with metastatic lung cancer and ECOG PS ≥ 3 were excluded. The primary endpoint was determined as OS. When LabPS scores were evaluated using receiver operating characteristic curve analysis, patients were classified into 2 prognostic groups: “favorable” (≤1) and “unfavorable” (>1), with an area under the curve corresponding to a 95% confidence interval: 0.654 to 0.806. Patients were stratified according to both their TNM stage and LabPS score, and survival analyses were subsequently conducted. These analyses demonstrated that patients with early-stage disease and a favorable LabPS score had significantly longer OS. In this study, the LabPS score successfully stratified patients with SCLC and non-SCLC into prognostic groups, demonstrating significant survival differences between the favorable and unfavorable categories. These findings suggest that the LabPS score has potential for survival prediction. Because the LabPS score can be easily calculated using routine laboratory tests in combination with PS, it has the potential to serve as a practical and cost-effective tool in daily oncology practice, pending further validation in larger, prospective cohorts. If validated in future studies, this score may potentially assist in clinical decision-making, including the timing of chemoradiotherapy, radiation dose optimization, and the development of personalized treatment plans.Keywords
This publication has 14 references indexed in Scilit:
- The LabPS scoreAmerican Journal of Clinical Oncology, 2023
- Naples prognostic score as a predictor of outcomes in lung cancer: a systematic review and meta-analysis2023
- Preoperative Anemia is Associated With Worse Long-Term Survival After Lung Cancer Resection: A Multicenter Cohort Study of 5,029 PatientsJournal of Cardiothoracic and Vascular Anesthesia, 2022
- ECOG performance status ≥2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors—A systematic review and meta-analysis of real world dataLung Cancer, 2020
- The usefulness of lactate dehydrogenase measurements in current oncological practiceCellular & Molecular Biology Letters, 2020
- C-reactive protein is a significant predictor of improved survival in patients with advanced non-small cell lung cancer.Medicine, 2019
- Combining standard clinical blood values for improving survival prediction in patients with newly diagnosed brain metastases—development and validation of the LabBM scoreNeuro-Oncology, 2017
- Prognostic significance of serum LDH in small cell lung cancer: A systematic review with meta-analysisCancer Biomarkers, 2016
- The prognostic role of preoperative serum albumin levels in glioblastoma patientsBMC Cancer, 2015
- Pretreatment serum albumin as a predictor of cancer survival: A systematic review of the epidemiological literatureNutrition Journal, 2010